Evaluation of trovafloxacin in the treatment of Klebsiella pneumoniae lung infection in tumour-bearing mice
| Autor: | See Kean Chuah, Haragopal Thadepalli, Gary Rana, Umapathi Reddy, Nancy Hanna, Sastry Gollapudi |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Microbiology (medical)
Male medicine.drug_class Antibiotics Cefazolin Drug Evaluation Preclinical Biology Pharmacology Leukocyte Count Mice Anti-Infective Agents Ciprofloxacin Granulocyte Colony-Stimulating Factor medicine Pneumonia Bacterial Animals Pharmacology (medical) Naphthyridines Adverse effect Survival rate Antibacterial agent Antibiotics Antineoplastic Leukemia P388 Daunorubicin biochemical phenomena metabolism and nutrition Recombinant Proteins Granulocyte colony-stimulating factor Klebsiella Infections Trovafloxacin Klebsiella pneumoniae Infectious Diseases Mice Inbred DBA Immunology Drug Therapy Combination Neoplasm Transplantation medicine.drug Fluoroquinolones |
| Zdroj: | The Journal of antimicrobial chemotherapy. 45(1) |
| ISSN: | 0305-7453 |
| Popis: | Trovafloxacin, a new trifluoroquinolone, was evaluated for its therapeutic efficacy against Klebsiella pneumoniae lung infection in tumour (P388 murine leukaemia cells)-bearing mice, treated with or without a chemotherapeut ic agent, daunorubicin (DNR) and in mice without tumour. Its activity was compared with ciprofloxacin and cephazolin. The effect on therapeutic efficacy of the addition of recombinant granulocyte colony stimulating factor (rGCSF) was also examined. Our study showed that both quinolones successfully cured pneumonia owing to infection with K. pneumoniae in mice without tumours but that all antibiotics failed in tumour-bearing mice if DNR was withheld. Substantial differences were noted in DNR-treated tumour-bearing mice with infection—the cure rate with trovafloxacin was 91% whereas the cure rate with ciprofloxacin or cephazolin was 57%. Addition of rGCSF to ciprofloxacin did not substantially improve its efficacy (when assessed by protection against death owing to infection; the survival rate was 41%). Trovafloxacin cure rates ranged from 80 to 90% whether or not rGCSF was added to the treatment regimen. Our results suggest that prior cancer chemotherapy had no adverse effect on the therapeutic efficacy of trovafloxacin, and that trovafloxacin may be a promising therapeutic agent for treatment of bacterial infections in the presence of leucopenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|